Mainstream

Insmed outlines $405M–$425M ARIKAYCE revenue target as brensocatib nears launch and pipeline advances

Insmed outlines $405M–$425M ARIKAYCE revenue target as brensocatib nears launch and pipeline advances

Post ContentinsmRead More

You might also be interested in reading CFTC launches CEO Innovation Council for crypto oversight.

August 8, 2025
In Mainstream